Abstract
Obstructive sleep apnoea (OSA) conveys a substantial global public burden due to its high prevalence and causative relationship with cardiometabolic diseases. The current diagnostic reliance on the apnoea/hypopnoea index (AHI) is insufficient to address the complex, multifaceted condition, and a revision of the standard criteria is urgently needed. Together with a better understanding of the clinical, pathophysiological, and sleep diagnostic phenotypic characteristics, this will pave the way to personalised, holistic treatment approaches.